Monthly Archives: April 2012
Investment acknowledges groundbreaking progress and provides CPDC with additional resources to continue work to bring new radiopharmaceuticals for personalized cancer diagnosis and treatment to clinical use in Ontario.
HAMILTON ON and LONDON ON, (April 23, 2012)—Cancer research in Ontario, aimed at developing the next generation of radiopharmaceuticals, received a financial boost today. The Centre for Probe Development and Commercialization (CPDC) received a new four-year investment from the Ontario Institute for Cancer Research (OICR) of more than $2.9 million. The funding will enable CPDC to continue its groundbreaking work in developing and commercializing new radiopharmaceuticals that will help physicians to improve the non-invasive diagnosis and staging of cancer, select the best targeted therapies, assess the effectiveness of treatment in days rather than months, and improve outcomes for adult and pediatric cancer patients.